Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

By Li Jing   Brahmer Julie   Messersmith Wells   Hidalgo Manuel   Baker Sharyn  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 851-864

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 12, Iss. 6, 2011-06 ,pp. : 922-933

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations

By  

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1613-1628

Bentham Science Publishers

Access to resources Recommend Favorite

Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors

By  

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-05 ,pp. : 3883-3893

Bentham Science Publishers

Access to resources Recommend Favorite